Skip to main content

Table 1 Patient characteristics for cohort (n =24) being studied. Values were taken at the initiation of AZLI

From: The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

Characteristics of patient cohort

Responders (n = 14)

IQR

Non-responders (n = 10)

IQR

p value

Female sex

9

 

3

 

0.24

Median age, years

41.0

35.0–46.0

40.0

32.0–44.0

0.4

Median age at diagnosis, years

2.8

1.9–11.5

0.3

0.1–0.5

0.04

BMI (Kg/m2)

21.6

20.9–22.7

21.9

18.9–24.8

0.8

Lung disease status

 Mild FEV1 (≥70%)

1

 

1

  

 Moderate FEV1 (40–70%)

7

 

3

  

 Severe FEV1 (≤40%)

6

 

6

  

aMedian FEV1 (%) predicted at initiation

46.0

33.0–57.0

38.5

33.0–50.0

0.4

aMedian FEV1 (%) predicted post-initiation

45.0

35.0–57.0

33.5

30.0–48.0

0.2

Genotype

 ΔF508 homozyogous

8

 

6

  

 ΔF508 heterozygous

3

 

3

  

CF related co-morbidities

 Pancreatic insufficiency

12

 

10

  

 CF-related diabetes

4

 

4

  

 Impaired glucose tolerance

5

 

3

  

 Liver disease

1

 

1

  

 Bone disease

5

 

3

  

 Sinus disease

6

 

3

  

 Recurrent distal intestinal obstructive syndrome (DIOS)

4

 

1

  

Cultured Pathogens

  P. aeruginosa

14

 

10

  

  E. coli

1

 

0

  

 Methicillin susceptible S. aureus

0

 

3

  

 Group B streptococcus Spp.

1

 

0

  
  1. aRepresents the median of all spirometry values recorded in the year including those where a pulmonary exacerbation occurred